Tenex Health Inc., a Lake Forest, CA-based developer of minimally invasive therapies for removal of diseased soft tissue and restoration of healthy musculoskeletal function, closed a $5m Series A financing.
The round, which was led by VCI Partners.
The company intends to use the funds for product manufacturing, development of a sales force, and marketing initiatives.
Founded in 2009 by CEO Jagi Gill, Tenex Health launched the TX1 System in May 2011 after receiving 510(K) FDA clearance in February 2011.
Based on technology developed in collaboration with Mayo Clinic, the TX1 Tissue Removal System is a portable, self-contained system utilized in the FAST™ procedure—Focused Aspiration of Soft Tissue— for precise removal of diseased tendon tissue and related musculoskeletal tissue with intended use in the elbow, knee, ankle, foot, and shoulder.
The initial joints for intervention are the elbow and knee, with product launches addressing plantar fascia, shoulder, and Achilles injuries forthcoming.